SBIR/STTR Research Award

c-diGMP Signal Transduction Proteins are Biofilm Drug Targets

Award identifier bed90b0590bedd68ddb16c751fe163e3430dc609b55995049de990210695d7b2Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$367,815

Program and phase

SBIR · Phase I

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MICROBIOTIX, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
SCNKBDM341T1
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Cystic Fibrosis (CF) is a genetic disorder that affects the major airways of the lungs of more than 30,000 people in the United States. The altered airways of 80% of CF patients are afflicted with a persistent bacterial colonization by Pseudomonas aeruginosa. This pathogen is one of the terminal pathogens isolated from the CF lung and is highly associated with extensive pulmonary damage. P. aeruginosa is extremely difficult to eradicate in the CF lung using conventional antibiotic therapies. This results in recurrent bacterial infections of the lower respiratory tract, which are the primary cause of morbidity and mortality. Several lines of evidence indicate that colonization of the CF lung by P. aeruginosa involves the biofilm mode of growth. Most significantly, is that biofilms are up to 1000-fold more resistant to antibiotics and biocides than are planktonic bacteria. The biofilm mode of growth has not been considered in antibiotic drug discovery and development. In preliminary work, we have identified potential targets that are required for regulating biofilm formation. These novel targets are proteins containing GGDEF (diguanylate cyclase) and EAL (phosphodiesterase) motifs, which are involved in signal transduction pathways that utilize the secondary messenger cyclic- diGMP. These proteins represent a class of novel drug targets with biochemical activities that are amenable to high-throughput screening assays. Our overall goal is to discover and develop drugs that inhibit the biofilm mode of growth in P. aeruginosa. Our strategy for reaching this goal is to identify GGDEF/EAL motif- containing proteins essential for biofilm formation, validate them as targets for anti-biofilm drug discovery, and identify small molecules that inhibit them and disrupt biofilm formation and/or maintenance in P. aeruginosa. In this proposal we will achieve the following specific aims: (1) Identify GGDEF/EAL mutants that affect the regulation of biofilm formation in P. aeruginosa PA01. (2) Verify that the activities of GGDEF/EAL proteins required for modulating c-diGMP levels are essential for specifically regulating biofilm formation in several isolates of P. aeruginosa. (3) Identify additional components of the c-diGMP-dependent signaling pathway(s) and their effectors that are involved in regulating biofilm formation for verified GGDEF/EAL biofilm targets.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

85 SBIR/STTR records share this UEI (2001–2025). Reported award amounts total $75,824,388. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.